[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arrythmia-cardiac\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arrythmia-cardiac":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,85,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100637216","pharmacy-based-opportunistic-atrial-fibrillation-screening-integrated-with-emergency-services-numaplus-fa-100637216",false,"NCT07598903","Pharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA)","Pharmacy-based Opportunistic Screening for Atrial Fibrillation Using a Portable ECG Device Integrated With Emergency Medical Services: a Prospective Type-1 Hybrid Implementation Study (NUMAPLUS Project)","Numaplus_FA","Inclusion Criteria:\n\n1. Age 65 years or older\n2. Attending a participating community pharmacy for any routine healthcare purpose\n3. No prior documented or patient-reported diagnosis of atrial fibrillation\n4. Capacity to provide written informed consent\n\nExclusion Criteria:\n\n1. Confirmed prior diagnosis of atrial fibrillation\n2. Implanted pacemaker, implantable cardioverter-defibrillator (ICD) or other intracardiac device\n3. Clinically evident haemodynamic instability requiring direct emergency 061 activation (active chest pain, severe dyspnoea, syncope)\n4. Concurrent participation in another cardiac rhythm monitoring study\n5. Inability to maintain the required position for a 30-second ECG recording","ALL","65 Years",{"count":20,"type":21},380,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates the feasibility and fidelity of an opportunistic atrial fibrillation (AF) screening programme conducted in 38 community pharmacies in Seville (Spain), using the Kardias® 6-lead portable ECG device, coordinated with the emergency medical services centre Salud Responde (CES 061) and primary care physicians. Eligible participants are individuals aged 65 years or older without a prior AF diagnosis who attend a participating pharmacy for any routine purpose. The screening consists of a 30-second ECG recording performed by a trained community pharmacist. Positive or indeterminate results are transmitted in real time to Salud Responde for clinical validation and referral to primary care. The study is evaluated using the RE-AIM framework (Reach, Effectiveness, Adoption, Implementation, Maintenance). The primary outcome is protocol fidelity, measured by the Implementation Adherence Grade (IAG). The study is part of the NUMAPLUS project, funded by INTERREG VI-A España-Portugal (POCTEP 2021-2027), co-financed by the European Regional Development Fund (ERDF).",[27,28,29,30],"Atrial Fibrillation (Prevention of Stroke)","Arrythmia, Cardiac","Mass Screening","Pharmacies",[32,33,34,35,36,37,38,39],"atrial fibrillation","opportunistic screening","community pharmacy","RE-AIM","implementation science","emergency medical services","portable ECG","hybrid implementation study","NOT_YET_RECRUITING","2026-05-20",{"date":43,"type":44},"2026-05-22","ACTUAL",{"date":46,"type":21},"2026-06-01",{"date":48,"type":21},"2026-12-31",{"name":50,"class":51},"Centro de Emergencias Sanitarias 061 Andalucía","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":52},"100472987","phase-2-stereotactic-arrhythmia-radiotherapy-in-the-netherlands-no-2-100472987","NCT05439031","StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2","STARNL-2","Inclusion Criteria:\n\n* Age ≥18 years\n* Implanted ICD\n* World Health Organization (WHO) \u002F Eastern Cooperative Oncology Group (ECOG) performance status grade 0-3 in the past 3 months (from fully active to capable of limited self-care, see below for full explanation)\n* At least 3 episodes of treated VT within the last 3 months\n* Recurrence of VT after\n\n  * Failed or intolerant to least one class 1 or class 3 anti-arrhythmic drug AND\n  * At least one catheter ablation procedure OR considered to be unsuitable for a catheter ablation procedure (e.g. no sufficient vascular access, considered unfit to undergo prolonged general anesthesia, comorbid conditions resulting in unacceptable peri-procedural risks)\n* Able and willing to undergo all necessary evaluations, treatment and follow-up for the study and of follow-up thereafter\n\nExclusion Criteria:\n\n* Pregnancy\n* History of radiation treatment in the thorax or upper abdominal region\n* Interstitial pulmonary disease","18 Years",{"count":62,"type":21},12,[64],"PHASE2","Ventricular tachycardia (VT) is a malignant cardiac arrhythmia subjecting our patients to a high risk of sudden death, increased morbidity and reduced quality of life. Unfortunately, failure of treatment is common and VT recurrences remain an important concern. In these patients, stereotactic arrhythmia radiotherapy appears to be an effective and safe treatment. The mechanism of action however remains unknown and should be elucidated.\n\nThe objective of this phase 2, single arm, monocenter, pre-post intervention study is to evaluate the efficacy and safety of stereotactic arrhythmia radiotherapy and obtain insights in the mechanism of action by evaluating electro-anatomical alterations of stereotactic arrhythmia radiotherapy in patients with therapy refractory ventricular tachycardia.",[67,28],"Ventricular Tachycardia",[69,67,70,71,72,73,74],"Ventricular Arrhythmias","Cardiac Radioablation","Stereotactic Radiotherapy","Stereotactic Arrhythmia Radiotherapy","Stereotactic body radiotherapy","Cardiac ablative radiotherapy","RECRUITING","2026-01-13",{"date":78,"type":44},"2026-01-14",{"date":80,"type":44},"2023-05-19",{"date":82,"type":21},"2027-07",{"name":84,"class":51},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100607015","a-single-center-prospective-study-in-an-estimated-570-patients-who-underwent-genetic-screening-at-uz-brussel-in-the-context-of-a-primary-cardiac-arrhythmia-patients-showing-a-variant-class-34-or-5-in-scn4a-or-clcn1-will-undergo-a-clinical-and-electrophysiological-review-after-ic-100607015","NCT07183059","A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.","Exploring Overlap Between Primary Cardiac Arrhythmias and Non-dystrophic Myotonia: a Single Center Prospective Study.","Inclusion Criteria:\n\n* Patients with PCA who underwent a genetic analysis with a PCA gene panel since 2021 (since the panel involves 112 genes including SCN4A).\n* Male and female gender.\n\nExclusion Criteria:\n\n* Genetic analysis before 2021\n* Patients without cardiac screening in UZ Brussel","100 Years",{"count":94,"type":21},570,[24],"A prospective interventional single-center study will be conducted. The study includes clinically diagnosed Intramuros PCA-patients who underwent a PCA gene panel of 113 genes (see Appendix 1) in the UZ-Brussel since 2021. In a retrospective part of the study, we will assess cardiac history, cardiac family history, cardiac exams and medical treatment and genetic data and family history. The prevalence of a class 3, 4 or 5 variant in the SCN4A and CLCN1 gene in the PCA-group will be compared to controls who underwent genetic screening for different causes, in which no association with muscular channelopathies is expected, without access to their medical file. In a prospective part of the study, patients with PCA carrying a variant class 3,4 or 5 in the SCN4A gene or a variant class 3, 4 or 5 in the CLCN1 gene will be invited for a one day visit for an interview, clinical neurological assessment and EMG. The aim of this second phase is to describe the clinical presentation of patients with concomitant PCA and non-dystrophic myotonia .",[98,28],"Non Dystrophic Myotonia","2025-11-27",{"date":101,"type":44},"2025-12-01",{"date":103,"type":21},"2025-12-15",{"date":105,"type":21},"2027-09-30",{"name":107,"class":51},"Universitair Ziekenhuis Brussel",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":129,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100605065","cardiovascular-complications-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation-100605065","NCT07157670","Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","ALLOCARDIOTOX","Inclusion Criteria:\n\n* Age ≥ 15 years\n* Informed about the study and without objection to participation (or with consent from legal guardians)\n* Undergoing allogeneic HSCT\n\nExclusion Criteria:\n\n* Patient not followed up at the participating center\n* Pregnant or breastfeeding women\n* Patient not affiliated with social security\n* Patient under guardianship, curatorship, or legal protection","15 Years",{"count":117,"type":21},400,"OBSERVATIONAL","Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year. Conditioning and maintenance regimens carry a risk of both short- and long-term cardiotoxicity, leading to serious cardiovascular events including acute coronary syndrome (ACS), cardiac dysfunction, arrhythmias, pulmonary hypertension, and pericardial effusion. The pathophysiology of cardiotoxicity in HSCT patients remains poorly understood.\n\nIt is therefore crucial to investigate underlying mechanisms and identify predictive factors of cardiotoxicity in order to provide appropriate cardiological follow-up and management. Current European Society of Cardiology guidelines recommend routine monitoring of HSCT patients with echocardiography and cardiac biomarkers (NT-proBNP, troponin), although these recommendations are based on small-scale studies. The cardiodepressor factor DPP3 has shown promising results in cardio-oncology, with a causal role in anthracycline-induced cardiac dysfunction. Its role in HSCT-related cardiotoxicity requires further evaluation.\n\nThis multicenter study of HSCT recipients will be a valuable resource, enabling a better understanding of the pathophysiology of cardiotoxicity and prognosis. It will highlight imaging (echocardiography, calcium score, supra-aortic Doppler), electrocardiographic, and biological markers (including DPP3) associated with prognosis.",[121,122,123,124,125,126,28,127,128],"Cardiotoxicity","DPP3","HSCT","Allogeneic Hematopoietic Stem Cell Transplantation","ACS - Acute Coronary Syndrome","Cardiac Dysfunction","Pulmonary Hypertension","Machine Learning",[122,123,121,130,128],"Allogeneic hematopoietic stem cell transplantation","2025-09-02",{"date":133,"type":44},"2025-09-05",{"date":135,"type":21},"2025-09-15",{"date":137,"type":21},"2028-09-15",{"name":139,"class":51},"Assistance Publique - Hôpitaux de Paris"]